A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

David Lebowitz, an analyst from Citi, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The associated price target is ...

Alnylam reports interim phase 1 data of nucresiran showing rapid knockdown of TTR that is sustained at six months following a single dose: Cambridge, Massachusetts Tuesday, Novemb ...

Johnson & Johnson announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of ...